EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET FORECAST 2018-2026
KEY FINDINGS
Better regulatory policies have led to the increased trust in the drugs market, which is a key factor driving growth in the Europe ophthalmology drug and devices market. By the end of the forecast period of 2018-2026, the market is expected to progress with a CAGR of 5.80%.
MARKET INSIGHTS
Increased awareness in the region for ophthalmology drugs is the key opportunity for the European market growth. Also, increase in the prevalence rate of eye diseases is influencing a positive growth in the Europe market. The United Kingdom market accounted for the highest revenue share in 2017. The market is majorly driven by the rising prevalence of eye diseases and growing ageing population. On the other hand, it is the Russian ophthalmic drugs and devices market that is anticipated to exhibit the highest CAGR over the forecast period. The increased spending on the eye care is driving growth in the Russian market.
COMPETITIVE INSIGHTS
Noted market players include Novartis International Ag, Santen Pharmaceutical Co Ltd, Roche Holding Ag, Ziemer Group Holding Ag, Allergan Inc, Valent Pharmaceuticals International Inc, Essilor International S.A, Pfizer, Bayer, Johnson & Johnson Inc, Carl Zeiss Ag, and GlaxoSmithKline.
Better regulatory policies have led to the increased trust in the drugs market, which is a key factor driving growth in the Europe ophthalmology drug and devices market. By the end of the forecast period of 2018-2026, the market is expected to progress with a CAGR of 5.80%.
MARKET INSIGHTS
Increased awareness in the region for ophthalmology drugs is the key opportunity for the European market growth. Also, increase in the prevalence rate of eye diseases is influencing a positive growth in the Europe market. The United Kingdom market accounted for the highest revenue share in 2017. The market is majorly driven by the rising prevalence of eye diseases and growing ageing population. On the other hand, it is the Russian ophthalmic drugs and devices market that is anticipated to exhibit the highest CAGR over the forecast period. The increased spending on the eye care is driving growth in the Russian market.
COMPETITIVE INSIGHTS
Noted market players include Novartis International Ag, Santen Pharmaceutical Co Ltd, Roche Holding Ag, Ziemer Group Holding Ag, Allergan Inc, Valent Pharmaceuticals International Inc, Essilor International S.A, Pfizer, Bayer, Johnson & Johnson Inc, Carl Zeiss Ag, and GlaxoSmithKline.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. THE UK
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 4 EYE DRUGS GONE OFF-PATENT
TABLE 5 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 6 EUROPE DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 7 EUROPE DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 8 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 10 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 11 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 12 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 13 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 14 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 15 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 16 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 17 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 18 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 19 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 20 EUROPE DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 21 EUROPE SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 22 EUROPE SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 EUROPE SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 EUROPE SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 EUROPE DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 26 EUROPE DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 27 EUROPE DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 28 EUROPE DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 29 EUROPE DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 30 EUROPE DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 31 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 EUROPE DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 EUROPE DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 EUROPE DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 EUROPE DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 EUROPE DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 EUROPE DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 EUROPE DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 EUROPE DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 EUROPE DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 THE UK OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 FRANCE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 GERMANY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 15 SPAIN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 16 ITALY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 17 REST OF EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 18 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 19 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. THE UK
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 4 EYE DRUGS GONE OFF-PATENT
TABLE 5 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 6 EUROPE DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 7 EUROPE DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 8 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 10 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 11 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 12 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 13 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 14 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 15 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 16 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 17 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 18 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 19 EUROPE DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 20 EUROPE DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 21 EUROPE SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 22 EUROPE SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 EUROPE SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 EUROPE SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 EUROPE DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 26 EUROPE DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 27 EUROPE DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 28 EUROPE DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 29 EUROPE DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 30 EUROPE DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 31 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 EUROPE DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 EUROPE DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 EUROPE DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 EUROPE DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 EUROPE DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 EUROPE DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 EUROPE DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 EUROPE DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 EUROPE DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 THE UK OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 FRANCE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 GERMANY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 15 SPAIN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 16 ITALY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 17 REST OF EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 18 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 19 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
